Literature DB >> 19352467

Accomplishments in 2007 in the treatment of metastatic pancreatic cancer.

Christophe Louvet1, Philip A Philip.   

Abstract

Overview of the Disease IncidencePrognosisCurrent Therapy Standards ChemotherapyAccomplishments and Lack of Accomplishments During the Year TherapyBiomarkersBasic ScienceWhat Needs To Be Done (Application of the Accomplishments) Controversies and Disagreements When To Transition to a Phase III Study?What is the Optimum Design for Pilot Studies?Future Directions Comments on ResearchHow To Capture Data From Preclinical Research?Obstacles to ProgressConclusions.

Entities:  

Year:  2008        PMID： 19352467      PMCID： PMC2664908     

Source DB:  PubMed          Journal:  Gastrointest Cancer Res        ISSN： 1934-7820


  6 in total

1.  Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer.

Authors:  Asma Sultana; Catrin Tudur Smith; David Cunningham; Naureen Starling; John P Neoptolemos; Paula Ghaneh
Journal:  J Clin Oncol       Date:  2007-06-20       Impact factor: 44.544

2.  Gemcitabine-based combinations for inoperable pancreatic cancer: have we made real progress? A meta-analysis of 20 phase 3 trials.

Authors:  Emilio Bria; Michele Milella; Alain Gelibter; Federica Cuppone; Maria Simona Pino; Enzo Maria Ruggeri; Paolo Carlini; Cecilia Nisticò; Edmondo Terzoli; Francesco Cognetti; Diana Giannarelli
Journal:  Cancer       Date:  2007-08-01       Impact factor: 6.860

3.  Identification of pancreatic cancer stem cells.

Authors:  Chenwei Li; David G Heidt; Piero Dalerba; Charles F Burant; Lanjing Zhang; Volkan Adsay; Max Wicha; Michael F Clarke; Diane M Simeone
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

4.  Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.

Authors:  Malcolm J Moore; David Goldstein; John Hamm; Arie Figer; Joel R Hecht; Steven Gallinger; Heather J Au; Pawel Murawa; David Walde; Robert A Wolff; Daniel Campos; Robert Lim; Keyue Ding; Gary Clark; Theodora Voskoglou-Nomikos; Mieke Ptasynski; Wendy Parulekar
Journal:  J Clin Oncol       Date:  2007-04-23       Impact factor: 44.544

5.  Second-line chemotherapy in advanced pancreatic carcinoma: a multicenter survey of the Gruppo Oncologico Italia Meridionale on the activity and safety of the FOLFOX4 regimen in clinical practice.

Authors:  V Gebbia; E Maiello; F Giuliani; N Borsellino; M Caruso; G Di Maggio; F Ferraù; R Bordonaro; F Verderame; P Tralongo; L Di Cristina; R Agueli; P Russo; G Colucci
Journal:  Ann Oncol       Date:  2007-06       Impact factor: 32.976

6.  Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group.

Authors:  Richard Herrmann; György Bodoky; Thomas Ruhstaller; Bengt Glimelius; Emilio Bajetta; Johannes Schüller; Piercarlo Saletti; Jean Bauer; Arie Figer; Bernhard Pestalozzi; Claus-Henning Köhne; Walter Mingrone; Salomon M Stemmer; Karin Tàmas; Gabriela V Kornek; Dieter Koeberle; Susanne Cina; Jürg Bernhard; Daniel Dietrich; Werner Scheithauer
Journal:  J Clin Oncol       Date:  2007-06-01       Impact factor: 44.544
  6 in total
  7 in total

Review 1.  [Oligometastasis in pancreatic cancer : Current state of knowledge and spectrum of local therapy].

Authors:  F Gebauer; A I Damanakis; C Bruns
Journal:  Chirurg       Date:  2018-07       Impact factor: 0.955

Review 2.  Surgery for oligometastasis of pancreatic cancer.

Authors:  Fengchun Lu; Katherine E Poruk; Matthew J Weiss
Journal:  Chin J Cancer Res       Date:  2015-08       Impact factor: 5.087

3.  Preoperative evaluation of pancreatic ductal adenocarcinoma with synchronous liver metastasis: Diagnosis and assessment of unresectability.

Authors:  Hao-Jun Shi; Chen Jin; De-Liang Fu
Journal:  World J Gastroenterol       Date:  2016-12-07       Impact factor: 5.742

Review 4.  Advanced EUS Guided Tissue Acquisition Methods for Pancreatic Cancer.

Authors:  Pujan Kandel; Michael B Wallace
Journal:  Cancers (Basel)       Date:  2018-02-17       Impact factor: 6.639

5.  Analysis of a novel immune checkpoint, Siglec-15, in pancreatic ductal adenocarcinoma.

Authors:  Xianlong Chen; Shengwei Mo; Yue Zhang; Heng Ma; Zhaohui Lu; Shuangni Yu; Jie Chen
Journal:  J Pathol Clin Res       Date:  2022-01-27

6.  Portal vein resection and reconstruction with artificial blood vessels is safe and feasible for pancreatic ductal adenocarcinoma patients with portal vein involvement: Chinese center experience.

Authors:  Zhi-Bo Xie; Ji-Chun Gu; Yi-Fan Zhang; Lie Yao; Chen Jin; Yong-Jian Jiang; Ji Li; Feng Yang; Cai-Feng Zou; De-Liang Fu
Journal:  Oncotarget       Date:  2017-09-12

7.  Cathepsin D Expression and Gemcitabine Resistance in Pancreatic Cancer.

Authors:  Ujjwal M Mahajan; Elisabetta Goni; Enno Langhoff; Qi Li; Eithne Costello; William Greenhalf; Stephan Kruger; Steffen Ormanns; Christopher Halloran; Paula Ganeh; Manuela Marron; Felix Lämmerhirt; Yue Zhao; Georg Beyer; Frank-Ulrich Weiss; Matthias Sendler; Christiane J Bruns; Thomas Kohlmann; Thomas Kirchner; Jens Werner; Jan G D'Haese; Michael von Bergwelt-Baildon; Volker Heinemann; John P Neoptolemos; Markus W Büchler; Claus Belka; Stefan Boeck; Markus M Lerch; Julia Mayerle
Journal:  JNCI Cancer Spectr       Date:  2019-08-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.